3D-porous hybrid anti-inflammatory nanoscaffold for drug delivery and tissue engineering

Patent metadata

Field	Value
Publication number	US-12350404-B2
Application number	US-202016874313-A
Country	US
Kind code	B2
Filing date	May 14, 2020
Priority date	Nov 15, 2017
Publication date	Jul 8, 2025
Grant date	Jul 8, 2025

Abstract

The invention relates to biodegradable nanoscaffolds, e.g. low dimension manganese oxide (MnO 2 )-based nanoscaffolds containing ECM proteins and/or cationic polymers, and methods of use and manufacture thereof.

First claim

The invention claimed is:

1. A biodegradable scaffolding material comprising a hybrid support structure consisting of manganese dioxide support structures, and at least one of a plurality of extracellular matrix proteins or a plurality of extracellular matrix polysaccharides,
wherein the manganese dioxide support structures consist of two-dimension nanosheets;
wherein the manganese dioxide support structures define a structure comprising a plurality of interstices and
the plurality of extracellular matrix proteins or plurality of extracellular matrix polysaccharides are disposed around and between the manganese dioxide support structures and through the manganese dioxide support structure interstices;
wherein the extracellular matrix proteins or extracellular matrix polysaccharides have a binding affinity with the manganese dioxide support structures, and together form at least one 3-dimensional nanoscaffold, and
wherein either the nanoscaffold thickness, protein concentrations utilized to assemble the two-dimension nanosheets, or both, are selected in combination with the aspect ratio of the nanoscaffold to set the zero-order degradation rate of the nanoscaffold.

2. The biodegradable scaffolding material of claim 1 , wherein the extracellular matrix proteins comprise at least one of collagen, elastin, laminin, fibronectin, gelatin, a reconstituted basement membrane extracted from Engelbreth-Holm-Swarm mouse tumor, entactin, proteoglycans, or basement membrane protein.

3. The biodegradable scaffolding material of claim 2 , wherein the extracellular matrix proteins comprise laminin.

4. The biodegradable scaffolding material of claim 1 , wherein the extracellular matrix polysaccharides comprise at least one of hyaluronic acid, alginate, chitosan, or combinations thereof.

5. The biodegradable scaffolding material of claim 1 , further comprising at least one cell that is loaded onto the manganese dioxide support structures.

6. The biodegradable scaffolding material of claim 5 , wherein the at least one cell comprises stem cells.

7. The biodegradable scaffolding material of claim 6 , wherein the stem cells comprise neural stem cells.

8. The biodegradable scaffolding material of claim 1 , further comprising at least one therapeutic agent that is loaded onto the manganese dioxide support structures.

9. The biodegradable scaffolding material of claim 8 , wherein the therapeutic agent comprises at least one of a protein, antibody, nucleic acid, biologic drug, peptide, small molecule, ligand, cytokine, chemotherapeutic agent, antipyretic, analgesic, anesthetic, antibiotic, antiseptic, hormone, stimulant, depressant, statin, beta blocker, anticoagulant, antiviral, anti-fungal, anti-inflammatory, growth factor, vaccine, diagnostic composition, psychiatric medication, or psychoactive compound.

Assignees

• Univ Rutgers

Inventors

• Lee Ki-Bum
• Yang Letao
• Conley Brian

Classifications

• C12N5/0619

  Neurons · CPC title

• B82Y40/00

  Manufacture or treatment of nanostructures · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title